AstraZeneca PLC (AZN)

30.24
0.48 1.61
NYSE : Health Care
Prev Close 29.76
Open 30.20
Day Low/High 30.13 / 30.34
52 Wk Low/High 25.55 / 35.04
Volume 2.64M
Avg Volume 5.26M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 75.66B
EPS 1.40
P/E Ratio 13.41
Div & Yield 1.90 (6.40%)

Latest News

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

TAGRISSO® (osimertinib) Receives US FDA Full Approval

TAGRISSO® (osimertinib) Receives US FDA Full Approval

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for TAGRISSO ® (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth...

Astrazeneca Scores Milestone Victory in Oncology

Astrazeneca Scores Milestone Victory in Oncology

A double victory in oncology failed to lift Astra stock, amid broad weakness in European markets

Keep Trading AstraZeneca From the Long Side

Keep Trading AstraZeneca From the Long Side

The stock is headed toward a bullish golden cross.

New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result In Reduced Overall Costs In Preterm Infants Born At 29-32 WGA Who Are Less Than Three Months Of Age

New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result In Reduced Overall Costs In Preterm Infants Born At 29-32 WGA Who Are Less Than Three Months Of Age

AstraZeneca today announced new results data which evaluated the cost-effectiveness of SYNAGIS ® (palivizumab) for respiratory syncytial virus (RSV) in preterm infants 29-34 weeks gestational age compared to those...

AstraZeneca Shares Progress On LYNPARZA™ (olaparib) Tablets In The US

AstraZeneca Shares Progress On LYNPARZA™ (olaparib) Tablets In The US

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for LYNPARZA™ (olaparib) tablets (300mg twice daily) for use in platinum-sensitive,...

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.

AstraZeneca's CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations For Heart Failure And Death Versus Other Type-2 Diabetes Medicines

AstraZeneca's CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations For Heart Failure And Death Versus Other Type-2 Diabetes Medicines

AstraZeneca today announced results of the first large real-world evidence study of its kind evaluating the risk of hospitalization for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving...

European Markets Mixed, Auto Stocks Slide, U.S. Dollar Slumps

European Markets Mixed, Auto Stocks Slide, U.S. Dollar Slumps

European markets are mixed amid a pause in the global equity market rally after a slumping dollar helped Asia shares to their best weekly gain in more than six months.

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca said Friday that it had received a second "complete response letter" from the U.S. FDA regarding its Hyperkalaemia treatment, putting the drug's approval process in the United States doubt.

Goldman Sachs Raises Clovis Oncology Price Target to $75

Goldman Sachs Raises Clovis Oncology Price Target to $75

Clovis Oncology closed trading below $67 on Tuesday.

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Stocks declined on Tuesday as wild weather stifled activity and led to low volume.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

LYNPARZA™ (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy

LYNPARZA™ (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy

AstraZeneca today presented results from the Phase III SOLO-2 trial demonstrating a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer...

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, AZN, BDL, INGN, ITRI, PAH Downgrades: AGYS, ASFI, IKNX, PRFT, SIX, VNCE Initiations: SRG Read on to get TheStreet Quant Ratings' detailed report:

Wake Up Wall Street: Donald Trump to Address Congress

Wake Up Wall Street: Donald Trump to Address Congress

U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.

Global Financial News: Nikkei 225 Snaps Losing Streak

Global Financial News: Nikkei 225 Snaps Losing Streak

Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close

European Stocks Hold Cautious Gains Ahead of U.S Data, Trump Address to Congress

European Stocks Hold Cautious Gains Ahead of U.S Data, Trump Address to Congress

European stocks struggled to hold on to gains Tuesday as investors adopted cautious positioning ahead of key U.S. economic data and the first address to Congress by President Donald Trump.

AstraZeneca Shares Rise After FDA Approval for Type-2 Diabetes Treatment

AstraZeneca Shares Rise After FDA Approval for Type-2 Diabetes Treatment

AstraZeneca stock gained in early London trading Tuesday after it received approval from the U.S. Food and Drug Administration for a type-2 diabetes medication.

FDA Approves Once-Daily QTERN® (Dapagliflozin And Saxagliptin) Tablets For Adults With Type-2 Diabetes

FDA Approves Once-Daily QTERN® (Dapagliflozin And Saxagliptin) Tablets For Adults With Type-2 Diabetes

AstraZeneca (NYSE:AZN) today announced that the US Food and Drug Administration (FDA) has approved once-daily QTERN ® (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

AstraZeneca Has Started a Turnaround

AstraZeneca Has Started a Turnaround

The old saying that volume precedes price could be playing out

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Dow, S&P 500 and Nasdaq Close Out Strong Week With Fresh Records

Dow, S&P 500 and Nasdaq Close Out Strong Week With Fresh Records

The Dow, S&P 500 and Nasdaq rose slightly on Friday ahead of the long holiday weekend.